These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 35875370)

  • 1. The molecular pathophysiology of depression and the new therapeutics.
    Tian H; Hu Z; Xu J; Wang C
    MedComm (2020); 2022 Sep; 3(3):e156. PubMed ID: 35875370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
    DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
    Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency.
    Nikkheslat N
    Brain Behav Immun Health; 2021 Dec; 18():100383. PubMed ID: 34849492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives.
    Shin C; Kim YK
    Psychiatry Investig; 2020 Mar; 17(3):181-192. PubMed ID: 32209965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human induced pluripotent stem cells technology in treatment resistant depression: novel strategies and opportunities to unravel ketamine's fast-acting antidepressant mechanisms.
    Marcatili M; Sala C; Dakanalis A; Colmegna F; D'Agostino A; Gambini O; Dell'Osso B; Benatti B; Conti L; Clerici M
    Ther Adv Psychopharmacol; 2020; 10():2045125320968331. PubMed ID: 33224469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine for treatment-resistant unipolar depression: current evidence.
    Mathew SJ; Shah A; Lapidus K; Clark C; Jarun N; Ostermeyer B; Murrough JW
    CNS Drugs; 2012 Mar; 26(3):189-204. PubMed ID: 22303887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on ketamine and its two enantiomers as rapid-acting antidepressants.
    Zhang K; Hashimoto K
    Expert Rev Neurother; 2019 Jan; 19(1):83-92. PubMed ID: 30513009
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid-Acting Antidepressants: Mechanistic Insights and Future Directions.
    Gerhard DM; Duman RS
    Curr Behav Neurosci Rep; 2018 Mar; 5(1):36-47. PubMed ID: 30034992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketamine: A tale of two enantiomers.
    Jelen LA; Young AH; Stone JM
    J Psychopharmacol; 2021 Feb; 35(2):109-123. PubMed ID: 33155503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ketamine's antidepressant effect: focus on ketamine mechanisms of action].
    De Maricourt P; Jay T; Goncalvès P; Lôo H; Gaillard R
    Encephale; 2014 Feb; 40(1):48-55. PubMed ID: 24434007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.
    Iadarola ND; Niciu MJ; Richards EM; Vande Voort JL; Ballard ED; Lundin NB; Nugent AC; Machado-Vieira R; Zarate CA
    Ther Adv Chronic Dis; 2015 May; 6(3):97-114. PubMed ID: 25954495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders.
    Costi S; Van Dam NT; Murrough JW
    Curr Behav Neurosci Rep; 2015 Dec; 2(4):216-225. PubMed ID: 26783510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agmatine as a novel candidate for rapid-onset antidepressant response.
    Valverde AP; Camargo A; Rodrigues ALS
    World J Psychiatry; 2021 Nov; 11(11):981-996. PubMed ID: 34888168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.
    Zhu W; Ding Z; Zhang Y; Shi J; Hashimoto K; Lu L
    Neurosci Bull; 2016 Dec; 32(6):557-564. PubMed ID: 27878517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers.
    Scotton E; Antqueviezc B; Vasconcelos MF; Dalpiaz G; Paul Géa L; Ferraz Goularte J; Colombo R; Ribeiro Rosa A
    Biochem Pharmacol; 2022 Apr; 198():114963. PubMed ID: 35182519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study.
    Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G
    JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action.
    Irwin MN; VandenBerg A
    Ment Health Clin; 2021 May; 11(3):200-210. PubMed ID: 34026396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.